Bisphosphonates for Osteoporosis — Where Do We Go from Here?

In response to reports of rare but serious adverse events associated with bisphosphonates, the FDA reviewed long-term bisphosphonate efficacy. Two FDA committees recommended an update to bisphosphonate labeling but no regulatory restriction on duration of use.